Highlights

  • Micro-X Limited (ASX:MX1) develops compact X-ray and CT systems for medical and security applications.
  • The company released its FY26 annual report in August 2026 and updated its funding arrangements in October.
  • A September 2026 announcement addressed an extension to its US homeland-security baggage-scanner program.
  • At the time of writing on 19 October 2026, MX1 traded at AUD 0.060, up 3.45% during the session.

Micro-X Limited (ASX:MX1) develops compact X-ray imaging technology for hospitals, emergency services and security screening. Its commercial mobile radiography products sit alongside development programs covering stroke diagnosis, portable computed tomography (CT) and passenger baggage inspection. The company entered October 2026 following its full-year financial reporting, a further US security-scanner contract update and a disclosure concerning convertible-note funding. Those developments place product delivery, research milestones and capital management in focus. At the time of writing on 19 October 2026, Micro-X shares were trading at AUD 0.060, recording a 3.45% increase during the day’s trading session.

Company Business

Micro-X designs its imaging equipment around proprietary Nano Electronic X-ray (NEX) technology. The platform uses electronically controlled X-ray emitters and purpose-built high-voltage components, allowing the company to develop smaller imaging devices than conventional configurations. Its design and production operations are based at Tonsley in South Australia, with a US team supporting engineering and commercial activities.

The Rover range provides mobile digital radiography for clinical settings, including care delivered at the patient’s bedside. The development portfolio includes a miniature Head CT system intended for stroke assessment outside conventional imaging suites and a mobile full-body CT project. In security, the company has worked on a miniature baggage CT scanner, self-screening airport checkpoints and its Argus X-ray camera for defence and specialist inspection tasks. These activities have different development, testing and sales cycles.

Recent Development

In October 2026, Micro-X announced an update to its convertible-note funding and issued the notice for its 2026 annual general meeting. The funding disclosure makes the terms and timing of capital support relevant to ongoing operations, while the meeting provides a formal occasion for shareholders to consider scheduled corporate business.

In late September 2026, the company reported an extension to the US Department of Homeland Security CT baggage-scanner contract. The technology uses a modular scanner design intended for security inspection, and the US program has included development of automated detection capabilities. Contract-backed engineering work should be distinguished from recurring sales of completed commercial systems.

Earlier in 2026, Micro-X disclosed the start of a human imaging study involving its Head CT system and completion of a critical design review for its full-body CT program. It also announced additional funding for lung CT research. These are development-stage milestones: subsequent technical evaluation, clinical evidence, customer acceptance and any necessary regulatory clearances remain separate steps.

Financial Performance and Sector Context

Micro-X released its Appendix 4E and 2026 annual report in August, followed by further corporate and capital-related announcements. The FY26 report is the relevant source for audited revenue, expenditure, net result and year-end cash. Annual results require separating recognised operating revenue from grant receipts, development contracts and other funding arrangements; project awards should not automatically be treated as revenue for the period.

The business combines sales of finished mobile X-ray equipment with externally funded development activities. Consequently, the value and timing of an awarded research or engineering contract do not necessarily match cash receipts or revenue recognised in a reporting period. Working-capital requirements, production costs and spending on product development also affect the interpretation of reported operating cash flow.

The medical-imaging market is shaped by hospital procurement procedures, device performance requirements, clinical validation and regulation. Airport security equipment faces separate certification, integration and purchasing processes. Micro-X operates across both areas, but each depends on different buyers and approval pathways.

Risks to Consider

A central operational risk is the time needed to progress prototypes into accepted products and repeat customer orders. Technical testing, clinical studies, regulatory processes and manufacturing readiness can extend delivery schedules. Security programs also depend on government procurement decisions and contract stages. Funding requirements deserve attention because continued research, staff costs and manufacturing activities can precede commercial cash receipts. Convertible instruments may have repayment or conversion terms that affect the capital structure.

What to Watch Next

The next quarterly activities and cash-flow report will provide an updated view of receipts, expenditure and available funding. Other relevant developments include results from Head CT human imaging work, the next stages of full-body CT design and testing, and progress under the baggage-scanner contract extension. Investors can also monitor Rover orders and deliveries, developments in partner-funded research, and the company’s disclosures regarding convertible notes and shareholder meeting outcomes.

Key Insights

Micro-X is pursuing commercial mobile radiography while developing medical and security CT applications using a shared imaging technology platform. Its 2026 disclosures point to ongoing work across clinical testing, US government-supported security development and funding arrangements. The distinction between engineering milestones, product sales and cash generation remains important when assessing the company’s reported position. Upcoming financial statements, contract progress and product-validation announcements should provide further evidence of execution.